NCT02047474 2026-03-06
Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer
Yale University
Phase 2 Completed
Clinical Trials
49 trialsNCT02890355 2026-03-05
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04683315 2026-03-05
PANCREAS
Medical College of Wisconsin
Phase 2 Recruiting
NCT04233866 2026-03-02
Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel With 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients With Pancreatic Cancer That Has Spread
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT06381154 2026-01-30
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Mayo Clinic
Phase 2 Recruiting
NCT05026905 2026-01-20
A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer
National Health Research Institutes, Taiwan
Phase 2 Active not recruiting
NCT03322995 2026-01-08
PANC
Medical College of Wisconsin
Phase 2 Recruiting
NCT05945823 2025-12-29
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
Phase 2 Active not recruiting
NCT04390399 2025-12-15
Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT06941857 2025-12-03
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Recruiting
NCT04141995 2025-08-07
FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer
University of Nebraska
Phase 2 Terminated
NCT03822936 2025-02-13
PIOPPO
CNAO National Center of Oncological Hadrontherapy
Phase 2 Terminated
NCT05546411 2024-12-17
A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT05859750 2024-12-16
A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
Akeso
Phase 2 Recruiting
NCT01905150 2024-12-11
Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer
Bruckner Oncology
Phase 2 Completed
NCT06094140 2024-12-03
NEO-IMPACT
Australasian Gastro-Intestinal Trials Group
Phase 2 Active not recruiting
NCT06538623 2024-08-27
Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer
Ruijin Hospital
Phase 2 Recruiting
NCT04672005 2024-05-16
Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer
Rutgers, The State University of New Jersey
Phase 2 Active not recruiting
NCT04371224 2024-04-19
NaliCap
Seoul National University Hospital
Phase 2 Recruiting
NCT04447092 2024-04-19
Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer
Seoul National University Hospital
Phase 2 Active not recruiting
NCT05048524 2024-03-27
Peri-operative SLOG for Localized Pancreatic Cancer
National Health Research Institutes, Taiwan
Phase 2 Recruiting
NCT06210360 2024-01-18
Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX
Changhai Hospital
Phase 2 Not yet recruiting
NCT01897454 2023-12-05
Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer
Albert Einstein College of Medicine
Phase 2 Terminated
NCT01959672 2023-10-10
Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer
University of Nebraska
Phase 2 Completed
NCT00089024 2023-09-29
Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
University of Nebraska
Phase 2 Completed
NCT01726582 2023-08-14
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Phase 2 Completed
NCT02578732 2023-05-06
FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
Brown University
Phase 2 Completed
NCT02028806 2023-02-16
mFOLFIRINOX as First-Line Chemotherapy in Treating Chinese Patients With Metastatic Pancreatic Cancer
Sun Yat-sen University
Phase 2 Completed
NCT03099265 2022-10-27
Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma
Yale University
Phase 2 Terminated
NCT02551991 2022-10-10
Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma
Ipsen
Phase 2 Completed
NCT04089150 2021-10-22
MASTERPLAN
Australasian Gastro-Intestinal Trials Group
Phase 2 Unknown
NCT01666730 2021-08-10
Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01652976 2021-01-05
FOLFOX-D
University of Florida
Phase 2 Completed
NCT01397019 2020-11-02
Chemotherapy for Patients With Locally Advanced Pancreatic Cancer (LAPC) With Additional Chemo-radiotherapy (CRT) for Patients With Borderline Resectable Tumours
Odense University Hospital
Phase 2 Completed
NCT01821729 2020-09-25
Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer
Massachusetts General Hospital
Phase 2 Unknown
NCT02405585 2020-05-28
Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer
Lumos Pharma
Phase 2 Terminated
NCT02345460 2018-07-13
Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT01688336 2017-10-06
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Terminated
NCT03167112 2017-08-29
Folfirinox
McGill University Health Centre/Research Institute of the McGill University Health Centre
Phase 2 Unknown
NCT01581307 2017-03-03
Phase II Trial Evaluating OS With Therasphere® + 2nd-Line FOLFOX in Pancreatic Liver Mets
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01050426 2016-10-14
PERU
Royal Marsden NHS Foundation Trust
Phase 2 Terminated
NCT00002955 2014-05-22
Combination Chemotherapy in Treating Patients With Advanced Cancer of the Pancreas
University of Southern California
Phase 2 Completed
NCT01074996 2014-01-16
APC-S1
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Phase 2 Unknown
NCT01867892 2013-06-04
A Phase II Study of Locally Advanced Pancreatic Cancer
National Health Research Institutes, Taiwan
Phase 2 Unknown
NCT00003018 2013-01-03
S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer
SWOG Cancer Research Network
Phase 2 Completed
NCT00919282 2009-06-12
GFF
CONKO-Studiengruppe
Phase 2 Completed
NCT00010088 2009-02-09
Chemotherapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas or Bile Duct
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00149578 2007-05-17
A Phase II Study of Combine Modality Therapy in Locally Advanced Pancreatic Cancer
National Health Research Institutes, Taiwan
Phase 2 Unknown
NCT00323583 2007-05-08
Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer
Seattle Cancer Treatment and Wellness Center
Phase 2 Unknown